Skip to main content
Benjamin A. Yezer on Muck Rack

Benjamin A. Yezer

As seen in: Pharma Manufacturing
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Benjamin A.

Contact Benjamin A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Excipients Fit for 21st Century Medicine

|
By Joshua S. Katz, Abigail Nolin, Benjamin A. Yezer
| Pharma Manufacturing Verified
DuPont's novel excipient is designed to better stabilize biologics By Joshua S. Katz, Abigail Nolin, Benjamin A. Yezer, and Susan Jordan Pharma Excipients, DuPont Nutrition and Health, DowDuPont Specialty Products Division, The Dow Chemical Company Mar 11, 2019 As biologics continue to expand in the marketplace, they present a unique array of challenges for producers compared to conventional small molecule drugs.
Open in Who Shared Issue with article?

Dynamic Properties of Novel Excipient Suggest Mechanism for Improved Performance in Liquid Stabilization of Protein Biologics

|
By Joshua S. Katz, Susan Jordan, Abigail Nolin, Benjamin A. Yezer
| American Chemical Society
To improve liquid formulation stability, formulators employ various excipients designed to stabilize protein drugs, including buffers, salts, sugars, and surfactants. One of the roles of surfactants is to protect the protein drug from surface interactions that can destabilize the protein. Protein drug products formulated with surfactants usually contain either a polysorbate or poloxamer.
Open in Who Shared Issue with article?
See all 2 articles